Mark G. Foletta
Mark G. Foletta's purchase track record
Mark G. Foletta has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/29/2024 | AMN | $28K | -3.5% | -5.9% | +9.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
AMN Healthcare Maintains Outperform Rating, Target Raised to $43. Analyst BMO Capital kept an Outperform rating on AMN Healthcare and increased its price target to $43. The company announced a third‑quarter 2026 earnings conference call scheduled for November 5. The stock trades near its $33.96 support level and carries a trailing P/E of 13.4, while analysts’ average target is $36.14.
Transaction History
| DXCM | ▼ Sell | Open Market | 2,000 | $171K | 8/3/2026 | View on chart |
| DXCM | ▼ Sell | Open Market | 2,000 | $160K | 7/31/2026 | View on chart |
| DXCM | ▼ Sell | Open Market | 3,801 | $282K | 6/15/2026 | View on chart |
| DXCM | ▼ Sell | Open Market | 199 | $15K | 6/15/2026 | View on chart |
| AMN | ▼ Sell | Open Market | 2,000 | $62K | 6/15/2026 | View on chart |
| AMN | ▼ Sell | Open Market | 1,681 | $52K | 6/15/2026 | View on chart |
| DXCM | ▲ Buy | Grant | 6,331 | $0 | 5/28/2026 | View on chart |
| DXCM | ▼ Sell | Gift | 5,731 | $0 | 5/8/2026 | View on chart |
| DXCM | ▼ Sell | Gift | 5,731 | $0 | 5/8/2026 | View on chart |
| AMN | ▲ Buy | Option Exercise | 8,325 | $0 | 5/1/2026 | View on chart |
| DXCM | ▼ Sell | Open Market | 2,555 | $207K | 8/15/2025 | View on chart |
| DXCM | ▼ Sell | Open Market | 195 | $16K | 8/15/2025 | View on chart |
| DXCM | ▼ Sell | Open Market | 2,742 | $234K | 7/15/2025 | View on chart |
| DXCM | ▼ Sell | Open Market | 8 | $688 | 7/15/2025 | View on chart |
| DXCM | ▼ Sell | Open Market | 2,750 | $229K | 6/16/2025 | View on chart |
| DXCM | ▲ Buy | Grant | 5,731 | $0 | 5/8/2025 | View on chart |
| DXCM | ▼ Sell | Gift | 2,973 | $0 | 5/8/2025 | View on chart |
| DXCM | ▼ Sell | Gift | 2,973 | $0 | 5/8/2025 | View on chart |
| AMN | ▲ Buy | Option Exercise | 3,019 | $0 | 4/19/2025 | View on chart |
| DXCM | ▼ Sell | Open Market | 3,007 | $351K | 6/18/2024 | View on chart |
| DXCM | ▼ Sell | Open Market | 299 | $35K | 6/18/2024 | View on chart |
| DXCM | ▼ Sell | Open Market | 7 | $806 | 6/17/2024 | View on chart |
| DXCM | ▼ Sell | Open Market | 2,212 | $259K | 6/17/2024 | View on chart |
| DXCM | ▼ Sell | Open Market | 475 | $56K | 6/17/2024 | View on chart |
| DXCM | ▲ Buy | Grant | 2,973 | $0 | 5/22/2024 | View on chart |
| DXCM | ▼ Sell | Gift | 3,306 | $0 | 5/18/2024 | View on chart |
| DXCM | ▼ Sell | Gift | 3,306 | $0 | 5/18/2024 | View on chart |
| AMN | ▲ Buy | Option Exercise | 1,681 | $0 | 4/19/2024 | View on chart |
| AMN | ▲ Buy | Open Market | 500 | $28K | 2/29/2024 | View on chart |
| DXCM | ▲ Buy | Grant | 3,306 | $3 | 5/18/2023 | View on chart |
| DXCM | ▼ Sell | Gift | 4,488 | $0 | 5/18/2023 | View on chart |
| DXCM | ▼ Sell | Gift | 4,488 | $0 | 5/18/2023 | View on chart |
| AMN | ▲ Buy | Option Exercise | 1,458 | $0 | 4/21/2023 | View on chart |
| AMN | ▼ Sell | Open Market | 1,458 | $129K | 4/21/2023 | View on chart |
| AMN | ▼ Sell | Open Market | 4,989 | $421K | 4/11/2023 | View on chart |
| AMN | ▼ Sell | Open Market | 1,053 | $89K | 4/11/2023 | View on chart |
| AMN | ▼ Sell | Gift | 300 | $0 | 11/15/2022 | View on chart |
| DXCM | ▲ Buy | Grant | 1,122 | $1 | 5/20/2022 | View on chart |
| DXCM | ▼ Sell | Other | 1,054 | $0 | 5/19/2022 | View on chart |
| DXCM | ▼ Sell | Other | 1,054 | $0 | 5/19/2022 | View on chart |
| AMN | ▲ Buy | Option Exercise | 2,139 | $0 | 4/21/2022 | View on chart |
| DXCM | ▼ Sell | Open Market | 2 | $1K | 12/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 41 | $23K | 12/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 41 | $23K | 12/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 70 | $39K | 12/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 78 | $44K | 12/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 116 | $65K | 12/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 65 | $37K | 12/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 87 | $49K | 12/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 45 | $28K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 14 | $9K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 13 | $8K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 43 | $27K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 124 | $78K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 7 | $4K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 56 | $35K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 76 | $48K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 42 | $26K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 40 | $25K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 40 | $25K | 11/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 47 | $25K | 10/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 6 | $3K | 10/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 126 | $68K | 10/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 88 | $48K | 10/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 181 | $99K | 10/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 51 | $28K | 10/1/2021 | View on chart |
| DXCM | ▼ Sell | Open Market | 1 | $552 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
DexCom CONNECT study published in NEJM
The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.
DexCom CONNECT study published in NEJM. The New England Journal of Medicine published the DexCom CONNECT study, which supports using continuous glucose monitoring for people with Type 2 diabetes who do not take insulin. This finding expands the potential user base for DexCom's devices beyond insulin-dependent patients. The stock recently showed pre-market activity, and analysts maintain an average target price of $96.46.